The genetic case for cardiorespiratory fitness as a clinical vital sign and the routine prescription of physical activity in healthcare

Ken B. Hanscombe[1, 4], Elodie Persyn[1], Matthew Traylor[2], Kylie P. Glanville[4], Mark Hamer [3], Jonathan R. I. Coleman[4], Cathryn M. Lewis[1, 4]

[1]Department of Medical & Molecular Genetics, King's College London, London, United Kingdom, [2]Queen Mary University of London, London, United Kingdom, [3]Institute of Sport Exercise & Health, Division of Surgery and Interventional Science, University College London, London, United Kingdom, [4]Social, Genetic and Developmental Psychiatry Centre, King's College London, London, United Kingdom

Ken B. Hanscombe ken.b.hanscombe@kcl.ac.uk (corresponding author)
Elodie Persyn elodie.persyn@kcl.ac.uk
Matthew Traylor m.traylor@qmul.ac.uk
Kylie P. Glanville kylie.glanville@kcl.ac.uk
Mark Hamer m.hamer@ucl.ac.uk
Jonathan R. I. Coleman jonathan.coleman@kcl.ac.uk
Cathryn M. Lewis cathryn.lewis@kcl.ac.uk

Abstract

Background: Cardiorespiratory fitness (CRF) and physical activity (PA) are well-established predictors of morbidity and all-cause mortality. However, CRF is not routinely measured and PA not routinely prescribed as part of standard healthcare. The American Heart Association (AHA) recently presented a scientific case for the inclusion of CRF as a clinical vital sign based on epidemiological and clinical observation. Here, we leverage genetic data in the UK Biobank (UKB) to strengthen the case for CRF as a vital sign, and make a case for the prescription of PA.

Methods: We derived two CRF measures from the heart rate data collected during a submaximal cycle ramp test: CRF-vo2max, an estimate of the participants' maximum volume of oxygen uptake, per kilogram of body weight, per minute; and CRF-slope, an estimate of the rate of increase of heart rate during exercise. Average PA over a 7-day period was derived from a wrist-worn activity tracker. After quality control, 38,160 participants had data on the two derived CRF measures, and 75,799 had PA data. We performed genome-wide association study (GWAS) analyses by sex, and post-GWAS techniques to understand genetic architecture of the traits and prioritize functional genes for follow-up.

Results: We found strong evidence that genetic variants associated with CRF and PA influenced genetic expression in a relatively small set of genes in heart, artery, lung, skeletal muscle, and adipose tissue. These functionally relevant genes

were enriched among genes known to be associated with coronary artery disease (CAD), type 2 diabetes (T2D), and Alzheimer's disease (three of the top 10 causes of death in high-income countries) as well as Parkinson's disease, pulmonary fibrosis, and blood pressure, heart rate, and respiratory phenotypes. Genetic variation associated with lower CRF and PA was also correlated with several disease risk factors (including greater body mass index, body fat and multiple obesity phenotypes); a typical T2D profile (including higher insulin resistance, higher fasting glucose, impaired beta-cell function, hyperglycaemia, hypertriglyceridemia); increased risk for CAD and T2D; and a shorter lifespan.

Conclusions: Genetics supports three decades of evidence for the inclusion of CRF as a clinical vital sign. Given the genetic, clinical, and epidemiological evidence linking CRF and PA to increased morbidity and mortality, regular measurement of CRF as a marker of health and routine prescription of PA is a prudent strategy to support public health.

Keywords

cardiorespiratory fitness, physical activity, genetics, genome-wide association, UK Biobank

Background

Cardiorespiratory fitness (CRF) and physical activity (PA) are well-established predictors of morbidity and mortality (1, 2). CRF is such a strong predictor of cardiovascular health, all-cause mortality, and mortality attributable to various cancers, that in 2016 the American Heart Association (AHA) put forward a scientific case for measuring CRF as a clinical vital sign (3). The AHA recommended that, "(at) a minimum, all adults should have CRF estimated each year (…) during their annual healthcare examination". The AHA also noted that measurement of CRF provides "clinicians the opportunity to counsel patients regarding the importance of performing regular physical activity". That exercise is medicine, preventative and curative, has been known from antiquity – Hippocrates wrote the earliest known prescription for exercise about 2000 years ago (4). Today however, we do not yet routinely prescribe PA, nor do we measure CRF as part of a standard clinical assessment.

Sedentary lifestyles are a significant public health problem. For example, physical inactivity and poor diet were the second leading modifiable, behavioural cause of death in the US in 2000 and are expected to overtake tobacco to become the leading cause (5). Worldwide, physical inactivity was estimated to account for about 10% of premature mortality in 2008, an effect size similar to smoking and obesity (6). In 2013, the economic burden due to direct health-care costs, productivity losses, and disability-adjusted life-years attributable to physical inactivity was estimated at US$53.8 billion (7). This economic burden is reflected in the prevalence of physical inactivity worldwide: 28% in 2016 (23% for men, 32% for women) (8). Most people do not know what the recommended activity guidelines to maintain good health are. A UK British Heart Foundation (BHF) survey estimated about 60% of adults in the UK do not know the recommended minimum level of PA (https://www.bhf.org.uk/informationsupport/publications/statistics/physical-

inactivity-report-2017). Modifiable physiological characteristics like CRF and behaviours like regular exercise are affected by both environmental and genetic factors. Genetic factors, not addressed in the AHA review, can influence CRF and PA through multiple mechanisms including appetite for leisure activity, physiological response to exercise, and CRF response to PA. Critically, genetics can be leveraged to identify links between CRF, PA, and disease. Here we present the genetic case for the measurement of CRF as a clinical vital sign, and the routine prescription of PA.

CRF is typically measured with incremental exercise (resistance or workload) on a treadmill or cycle ergometer. In a sub-maximal test, CRF is estimated from extrapolating the workload to the age-estimated maximum heart rate. PA has most often been measured by self-report. Previous research has shown that CRF and PA are familial, with family and twin study estimates of their heritability varying widely (CRF: h^2=0.25 – 0.65 (9); PA: h^2=0 – 0.78, and 0.48 in the only study that objectively measured PA (10)). There has been some interest in variation in CRF response to exercise. Several candidate gene studies and one genome-wide association study (GWAS) have reported genetic variants associated with baseline CRF, or CRF change in response to exercise, but none was genome-wide significant or reliably replicated (11-13). Two GWASs of PA in the UK Biobank (UKB) reported three loci associated with accelerometer-measured 7-day average PA (SNP heritability, h^2_{SNP}=0.14), and none with self-reported PA (14, 15). The genetic contribution to CRF is poorly characterised, and our current understanding of the genetics of PA has not examined differences by sex.

In this study, we performed the largest genome-wide association analysis of CRF, a GWAS of PA, and related their genetic risk profiles to the known genetic risk for anthropomorphic phenotypes, metabolic traits, and chronic diseases. CRF and PA were objectively measured in the UKB (16). Given the multitude of mechanisms by which PA and CRF affect biology (3, 13, 17), the differences in physiognomy (e.g., body fat distribution (18, 19)), behavioural dynamics (e.g., motivators and context preferences (20)), we investigated sex-specific as well as sex-combined CRF and PA phenotypes. The previous UKB analyses of PA combined sexes and included sex as a covariate which by design identifies only genetic factors common to both sexes. Our aim in this study was to characterise the genetic contribution to CRF and PA highlighting genetic links to disease, and thus to strengthen the case for the inclusion of CRF as a clinical vital sign and make more cogent the argument for routine prescription of regular PA in healthcare.

Methods

Sample

UK Biobank. The UK Biobank (UKB) is a research study of over 500,000 individuals from across the United Kingdom. Participants aged 40 to 69 were invited to attend one of 22 assessment centres between 2006 and 2010. A comprehensive range of health-related data has been collected at baseline and follow up, including disease diagnoses and lifestyle information, with blood samples taken for genome-wide genotyping and a biomarker panel. Further data are available in follow up studies on different subsets of UKB participants, including CRF and PA data. All participants provided electronic signed consent (16, 21).

After phenotype and genotype QC described below, we had 38,160 (19,582 male, 18,578 female) participants with CRF data, and 75,799 (33,668 male, 42,131 female) participants with PA data. Supplementary **Table S1** shows details of the derivation of the final GWAS sample.

Phenotypes

Cardiorespiratory fitness – submaximal cycle ramp test.

CRF was assessed with a submaximal cycle ramp test which used a stationary bicycle and 4-lead electrocardiograph (ECG) to record heartrate data during pre-test, exercise and rest phases (approximately 15 seconds, 6 minutes, and 1 minute respectively). The cycle test procedure is described in detail in the UKB Cardio Assessment document (https://biobank.ctsu.ox.ac.uk/crystal/docs/Cardio.pdf). Cycle ramp test data were collected at two instances: from August 2009 at the end of the initial assessment visit 2006–2010 (instance 0), and the first repeat assessment visit 2012–2013 (instance 1). Completion status for the cycle ramp test was 'Fully completed' for a total of 90,206 participants: 71,675 at instance 0, and 18,531 at instance 1. For the 2,615 participants recorded as 'Fully completed' at both instances we selected test data from the initial assessment. We selected only samples in the lowest risk group that performed the Category 1 protocol (**Table S2**).

The raw heart rate data were noisy. **Figure 1**, panel **A**, shows raw heart rate data for 1,000 random participants. In addition to the test-specific criterion used to QC the data, we removed body mass index outliers (BMI > +/- 3SD), selected workload and heart rate data from the 'Exercise' phase of the test and narrowed this selection to the period within which participants were cycling at within 20% of the prescribed cadence, 60 revolutions per minute (RPM, **Figure 1**, panel **B**). Finally, we applied a Butterworth filter to the heart rate data (**Figure S1**). Full cycle ramp test QC is described in the supplementary Methods and listed in **Table S1**.

From this data, we derived two measures: *CRF-vo2max,* an estimate of the maximum volume of oxygen uptake per kilogram of body weight per minute; and *CRF-slope*, the rate of increase of heart rate. Specifically, heart rate (HR), workload (WL), age, and weight were used to estimate fitness assuming a linear relationship between WL and HR:

$$\text{HR·age·max} = 208 - 0.7 * \text{age}$$

$$\text{WL·HR·max} = (\text{HR·age-max} - \text{HR·start}) * \text{WL·end} / (\text{HR·end} - \text{HR·start})$$

$$\text{CRF-vo2max} = 7 + ((10.8 / \text{weight}) * \text{WL·HR·max})$$

Where HR·age·max is age-estimated maximum heart rate, age is age at recruitment, WL·HR·max is work load at age-estimated maximum heart rate, HR·start/ ·end are heart rate at the start and end of the exercise period, and WL·end=work load at the end of the exercise period. The coefficients 208 and 0.7 for age-estimated maximum heart

rate, and 7 and 10.8 for CRF-vo2max, are commonly used constants and were the values used in a previously study of CRF in the UKB (22-24).

The second measure, CRF-slope, only assumes a linear relationship during the test interval. We fitted a linear model to the Butterworth-filtered heart rate signal for each participant and retained the slope, β_1, as rate of increase of heart rate (**Figure S1**):

$$\text{heart rate} \sim \beta_0 + \beta_1 * \text{trend}.$$

The term 'trend' refers to the time points at which repeated measurements of heart rate, workload, and cadence were taken within each phase of the submaximal cycle ramp test (**Figure S1**). Samples with negative slopes were excluded. Finally, we excluded outliers (+/-3SD) for either CRF-vo2max or CRF-slope from both measures.

Physical activity – wrist-worn accelerometer.

PA in the UKB was measured continuously over a period of 7 days with a wrist-worn accelerometer in 103,712 participants, as an add-on measure after the initial assessment between June 2013 and January 2016. We used a wear-time adjusted 7-day average PA and filtered participants on the following test-specific variables: *Data quality, good wear-time* (90015)='Yes', *Data quality, good calibration* (90016)='Yes', *Data quality, calibration on own data* (90017)='Yes', and no *Data problem indicators* (90002). Finally, we excluded BMI and PA outliers (+/- 3SD). General PA quality control and calibration of raw accelerometer data and calculation of derived activity level are described in detail elsewhere (25).

Disease frequency

The top 10 global causes of death in high-income countries in 2016, as reported by the World Health Organization (WHO), are shown in **Table S3**, along with the relevant International Classification of Diseases revision 10 (ICD-10) codes. Ischaemic heart disease was the number 1 global cause of death among high-income countries; lower respiratory tract infections, ranked 6th, was the only communicable cause of death on the list. We used UKB in-patient hospital episode statistics (diagnoses recorded in ICD-10 codes) to retrieve disease frequency for the top 10 global causes of death, among the subsample with CRF or PA data (**Table S3** includes ICD-10 codes). We ranked participants by level of the phenotypes CRF-vo2max, CRF-slope, and PA after correcting for age and socioeconomic status (SES, Townsend deprivation index), divided the participants into twenty approximately equal-sized groups, and calculated the proportion in each group with a diagnosis for each of the 10 query diseases. These diagnoses were potentially received both before and after the cycle ramp test and the week in which participants wore the physical activity tracker. This analysis was performed separately in males and females, since there are differences in both disease prevalence, and in phenotype distribution by sex.

Genetic analyses

The full UKB sample were genotyped on one of two custom Applied Biosystems genotyping arrays: 49,950 on the UK Biobank Lung Exome Variant Evaluation (UK BiLEVE) Array, and 438,427 on the UK Biobank Axiom Array. The genetic data underwent standard GWAS QC and were imputed using IMPUTE4 to three reference panels by the UKB: the Haplotype Reference Consortium (HRC) and the merged UK10K and 1000 Genomes phase 3 reference panels. General genotyping considerations, raw genotype data QC, and genetic imputation procedures in the UKB are described in detail elsewhere (16). Details of available genetic data and associated metadata are described in UKB Resource 664 (http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=664).

Full details of GWAS QC and association parameters, and post-GWAS analyses including transcriptome-wide association (TWAS) and colocalization, gene-set enrichment, and genetic correlation, are included in the supplementary methods. We used the standard $p=5x10^{-08}$ as our genome-wide significant threshold, a conservative Bonferroni-corrected p-value for TWAS significance correcting for all genes tested in all tissues ($p=0.05/75,486=6.6x10^{-07}$), and a false-discovery rate (FDR) correction for gene-set enrichment and genetic correlation.

Analysis tools

For data analysis and figure creation we used both R (26) and Python 3 (27), in conjunction with the bioinformatic pipeline software Snakemake (28). We used the R package ukbtools (29) to parse all UKB data. Genetic data analyses were performed using PLINK 1.9 and 2.0 (30) , LDSC (31), FUSION (32), and the web-based tools FUMA (33) and LD Hub (34).

Results

Descriptive statistics and smoking and alcohol drinking status

Descriptive statistics for the CRF and PA phenotypes showed higher values for CRF-vo2max in males, and higher CRF-slope and PA in females (**Table S4**). Correlations between CRF and PA phenotypes, and age and BMI were all modest-to-moderate and negative (r=-0.1 – -0.4), except for CRF-slope and age which had a positive correlation in females (r=0.34, p<<0.01) (**Figure S2**). Correlations between CRF-vo2max and SES were not significant; between CRF-slope and SES, and PA and SES, correlations were significant but small ($|r|<0.1$). In the combined-sex sample, phenotypic correlations between our three traits were in the directions expected. CRF-vo2max and PA had a modest positive correlation (r=0.23, p<<0.01, among the subsample who performed both the submaximal cycle ramp test and participated in the 7-day PA monitoring, N=10,935). CRF-slope and PA were not significantly correlated (r=-0.01, p=0.42, N=10,935). The two fitness phenotypes, CRF-vo2max and CRF-slope were negatively correlated (r=-0.57, p<<0.01, N=38,804).

As a proxy for true resting heart rate, heart rate at the beginning of the exercise phase of the cycle ramp test was negatively correlated with CRF-vo2max (r=-0.27, p<<0.01, N=30,558), but uncorrelated with CRF-slope (r=-0.01, p=0.02, N=30,558).

Smoking and alcohol drinking status are sometimes considered confounding factors in analyses of CRF and PA. In our data, there were small differences in mean CRF-vo2max, CRF-slope, and PA by smoking and drinking status (**Table S5**), which contributed little to trait variance in linear regression models of all three phenotypes on age, sex, smoking status, and alcohol status (ΔR^2<=0.004 compared to a base model of age and sex, **Table S6**). We chose not to adjust for the effects of smoking and drinking status in order to obtain unbiased estimates of the genetic factors on CRF and PA. There is evidence that correcting for heritable covariates can lead to biased estimates of the influence of genetic factors (35).

Disease frequency

For the top 10 global causes of death in high-income countries in 2016, as reported by the World Health Organization (WHO), **Figure 2** shows the frequency at which each disease was observed in the UKB by level of CRF-vo2max, CRF-slope, and PA (after correcting for age and SES). Diagnosis frequency was generally lower in the subsample with CRF data who performed cycle ramp test protocol 1 compared to the subsample with PA data: by definition the protocol 1 group had the least health risk factors of those selected to perform the cycle ramp test. Given the difference in the phenotype distributions of the male and female subsamples, and the inherent difference in disease frequency by sex, disease frequency has to be interpreted separately by sex.

Disease frequency by CRF

The only notable disease frequency difference with respect to CRF, was between CRF-vo2max and diabetes mellitus (**Figure 2**). There was a slight reduction in diabetes mellitus in the female sample with increasing CRF-vo2max, but the pattern is more clearly seen in the male sample in which frequency of diabetes mellitus diagnosis reduced from 5.4% in the least fit group to 1.0 % in the most fit group.

Disease frequency by PA

The clearest pattern is seen in PA for ischaemic heart disease and diabetes mellitus, with a notable overall greater frequency of disease diagnosis in males (**Figure 2**). Ischaemic heart disease diagnosis fell from 10.8% in the most physically active group to 3.0% in the least active group in the male sample, and 3.6% to 0.9% in the female sample. Similarly, diabetes mellitus diagnosis reduced from 7.2% to 0.8% in the male sample, and 4.1% to 0.4% in the female sample, between the least and most physically active groups. There were also reductions in disease diagnosis frequency with increasing PA in: lower respiratory tract infection (frequency in least and most physically active groups: males 3.0%

to 0.5%, females 2.6% to 0.9%), kidney disease (males 3.0% to 0.7%, female 1.4% to 0.4%), stroke (males 2.6% to 0.3%, females 1.2% to 0.3%), and chronic obstructive pulmonary disease (males 1.9% to 0.1%, females 1.3% to 0.2%).

Genetic associations

Genome-wide association studies were performed for CRF-vo2max, CRF-slope, and PA with results for male, female, and the combined sample (**Figure 3**). An annotated list of the independent genome-wide significant variants, determined by LD clumping of the association results, is included in **Table 1**. Supplementary **Figures S3–S11** are the regional plots for each sex-combined GWAS signal peak, and sex-specific GWAS signal peaks where there was evidence of heterogeneity.

Sex-combined results

We found one significant locus for CRF-vo2max and eight independent loci for CRF-slope, in the combined sample (**Table 1**). For PA, we found three independent loci on chromosome 17, however, two of these loci are situated within the large 17q21.31 inversion polymorphism (43,624,578 – 44,525,051 MB, human genome build 37 coordinates) and may not reflect independent causal variants (36, 37). Comparison of results from our combined sample PA with the three previously reported GWAS significant loci (15) showed consistency at the chromosome 17 locus, but weaker support at the chromosome 10 ($p=4.4x10^{-05}$) and 18 loci ($p=6.1x10^{-07}$) (**Table S7**) as a result of different analysis and QC considerations (**Table S1**).

284 **Table 1. GWAS significant ($p < 5x10^{-08}$) SNP associations**

SEX	CHR	BP	SNP	LOCUS	REF	ALT	A1	A1 FREQ	N	β	SE	P	P (other sex)
CRF-vo2max													
combined	6	122089704	rs58730006	intergenic[1]	AT	A	AT	0.10	38160	-0.604	0.107	$1.5x10^{-08}$	–
male[a]	6	126349980	rs1268122	*TRMT11*	G	G	T	0.34	19582	-0.546	0.099	$3.6x10^{-08}$	$1.7x10^{-01}$
CRF-slope													
combined	1	45003255	rs156653	*RNF220*	C	T	T	0.28	38160	-0.006	0.001	$6.0x10^{-09}$	–
combined	8	10758496	rs12542037	*XKR6*	A	G	A	0.45	38160	-0.006	0.001	$2.8x10^{-11}$	–
combined	8	8383140	rs61296026	intergenic[2]	G	T	G	0.48	38160	-0.006	0.001	$1.3x10^{-10}$	–
combined	8	11422494	8:11422494_AT_A	intergenic[3]	A	AT	A	0.48	38160	-0.005	0.001	$1.0x10^{-08}$	–
combined	8	8970762	rs7830804	*ERI1*	T	G	G	0.38	38160	-0.006	0.001	$8.9x10^{-09}$	–
combined	10	102556453	rs4551692	*PAX2*	A	G	G	0.12	38160	0.009	0.001	$1.5x10^{-09}$	–
combined	12	33537387	rs1343676	*SYT10*	C	T	T	0.49	38160	-0.006	0.001	$3.6x10^{-09}$	–
combined	12	24762501	rs11047527	intergenic[4]	C	A	C	0.15	38160	0.008	0.001	$1.4x10^{-08}$	–
male[b]	12	33537387	rs1343676	*SYT10*	C	T	T	0.49	19582	-0.006	0.001	$4.4x10^{-08}$	$1.6x10^{-03}$
female[c]	8	10758496	rs12542037	*XKR6*	A	G	A	0.44	18578	-0.009	0.002	$2.2x10^{-08}$	$9.8x10^{-04}$
female[d]	8	8383140	rs61296026	intergenic[2]	G	T	G	0.49	18578	-0.009	0.002	$4.0x10^{-08}$	$5.2x10^{-04}$
PA													
combined	17	43971206	17:43971206_CTAATT_C	*MAPT-AS1*	C	CTAATT	C	0.21	75799	0.293	0.046	$2.0x10^{-10}$	–
combined	17	44487793	rs4280294	*NSFP1*	C	G	C	0.22	75799	0.273	0.045	$1.9x10^{-09}$	–

combined	17	43463493	rs79724577	intergenic[5]	C	A	C	0.18	75799	0.276	0.048	$1.1x10^{-08}$	–
male[e]	6	76636384	rs67693719	*IMPG1*	C	T	C	0.33	33668	-0.344	0.061	$1.3x10^{-08}$	$8.4x10^{-01}$
female[f]	17	43971206	17:43971206_CTAATT_C	*MAPT-AS1*	C	CTAATT	C	0.22	42131	0.354	0.061	$6.2x10^{-09}$	$1.8x10^{-03}$

Note. These are independent SNP associations determined by p-value informed LD clumping (SNPs correlated 0.2 or greater in a 500 kb). β = standardized beta; SE = standard error of the standardized beta

[a] female β = -0.125, SE = 0.092: Q = 9.74, p = 1.8 x 10^{-03}; I^2 = 89.7%, 95% CI = 62.0% – 97.2%
[b] female β = -0.005, SE = 0.002: Q = 0.37, p = 5.4 x 10^{-01}; I^2 = 0.0% (ns = not significant at 0.05/6)
[c] male β = -0.004, SE = 0.001: Q = 7.01, p = 8.1 x 10^{-03}; I^2 = 85.7%, 95% CI = 42.7% – 96.5%
[d] male β = -0.004, SE = 0.001: Q = 6.12, p = 1.3 x 10^{-02}; I^2 =83.7%, 95% CI = 32.4% – 96.1% (ns)
[e] female β = -0.011, SE = 0.052: Q = 17.4, p < 0.0001; I^2 = 94.2%, 95% CI = 82.0% – 98.2%
[f] male β = 0.220, SE = 0.070: Q = 2.08, p = 1.5 x 10^{-01}; I^2 = 51.8%, 95% CI = 0.0% – 87.9% (ns)

[1] 631.0kb downstream of *HSF2* (heat shock transcription factor 2), 318.8kb upstream of *GJA1* (gap junction protein alpha 1)
[2] 176.5kb downstream of *CLDN23* (claudin 23), and 143.8kb upstream of *SGK223* (sugen kinase 223, alias for *PRAG1* – PEAK1 related, kinase-activating pseudokinase 1)
[3] 11.5kb downstream of *LINC00208* (long intergenic non-protein coding RNA 208), and 0.4kb upstream of *BLK* (B-lymphocyte kinase)
[4] 200.5kb downstream of *BCAT1* (branched chain amino acid transaminase 1) and 25.4kb upstream of *LINC00477* (long intergenic non-protein coding RNA 477)
[5] 7.8kb upstream of *ARHGAP27* (rho GTPase activating protein 27)

Sex-specific results

For CRF-vo2max we found one male-specific genome-wide significant signal rs1268122 (chr 6), with no evidence for association in females ($p=1.7x10^{-01}$), or the combined sample ($p=4.5x10^{-07}$), and significant effect size heterogeneity (Q=9.74, $p=1.8x10^{-03}$). This SNP was uncorrelated with the combined sample signal on the same chromosome ($r^2=1.3x10^{-05}$).

For CRF-slope, the one male and two female signals were also significant in the combined sample. Only the female specific SNP, rs12542037 (chr 8), showed evidence of an effect size difference between sexes: no evidence of association in males ($p=9.8x10^{-04}$), and significant effect size heterogeneity (Q=7.01, $p=8.1x10^{-03}$).

For PA, the one significant female signal was the top variant in the combined analysis and showed no evidence of heterogeneity. The male-specific SNP identified in PA, rs67693719 (chr 6), showed no evidence for association in females ($p=8.4x10^{-01}$), and significant heterogeneity (Q=17.4, p<0.0001).

Genes to prioritize for experimental follow-up

For each trait, we report genes identified as *functional* candidates by TWAS and colocalization analysis for *positional* candidates reported in **Table 1**. We then report any additional noteworthy TWAS-significant functional candidates. The functional candidates passing the TWAS multiple testing threshold (1 for CRF-vo2max, 22 for CRF-slope, and 28 for PA) are shown in **Figure 4**. Where functional candidates were also implicated in the gene-based association test these are indicated in **Figure 4**. The full list of significant genes from the gene-based test of association are shown in supplementary **Table S8**.

CRF-vo2max

The most significant GWAS SNP from the combined-sex CRF-vo2max analysis, rs5873006 (chr6), is intergenic. Neither flanking gene (*HSF2*, *GJA1*, **Table 1**) was a functional candidate. rs1268122 also on chromosome 6, identified in the male-only analysis is an intron variant in *TRMT11* (tRNA methyltransferase 11 homolog), and 48.6kb downstream of *HINT3* (histidine triad nucleotide binding protein 3). Functional analyses suggested a shared SNP driving the association in CRF-vo2max and expression of *HINT3* in skeletal muscle (male: TWAS p-value, $p_{TWAS}=5.6x10^{-7}$, PP4=0.97).

CRF-slope

The chromosome 1 association rs156653 is an intron variant in *RNF220* (ring finger protein 220), a promoter flanking region variant, and a transcription factor binding site variant. Functional analyses showed no evidence of association of *cis* expression of *RNF220* with CRF-slope in any of the tissues tested.

LD clumping suggests 4 independent signals on chromosome 8. rs12542037 is an intron variant in *XKR6* (XK related 6), rs61296026 and 8:11422494_AT_A are intergenic, and rs7830804 is an intron variant of *ERI1* (exoribonuclease 1). *BLK* (B lymphocyte kinase), 0.4 kb downstream of 8:11422494_AT_A, is a promoter/ enhancer for *FAM167A* (family with sequence similarity 167 member A), identified as a functional candidate for CRF-slope with evidence the same variant is driving CRF-slope association and expression of *FAM167A* in heart (atrial appendage) tissue (p_{TWAS}=1.6x10^{-07}, PP4=0.74). *ERI1* expression in lung was significant, but with little evidence the same variant drives expression and the CRF-slope association (p_{TWAS}=6.1x10^{-08}, PP4=0.19).

On chromosome 10, rs4551692 is an intron variant in *PAX2* (paired box 2), a non-coding transcript variant, and a non-sense mediated decay transcript variant. On chromosome 12 we identified 2 variants. rs1343676 is an intron variant in *SYT10* (synaptotagmin 10) and a non-sense mediated decay transcript variant, and has previously been reported to be associated with resting heart rate (38). rs11047527 is an intergenic variant.

In addition to the chromosome 8p23.1 functional candidates *FAM167A* and *ERI1,* we identified TWAS-significant candidates on chromosome 7q22.1: *TRIP6* (thyroid hormone receptor interactor 6) in blood, *SRRT* (serrate, RNA receptor molecule) in heart (atrial appendage) tissue, and *ACHE* (acetylcholinesterase) in adipose (visceral omentum), artery (aorta and tibial), and heart (atrial appendage) tissue. Each of these had high probability of a shared SNP driving both the CRF-slope association and expression in the particular tissue (PP4=0.99).

PA

LD clumping suggests 3 independent loci on chromosome 17: 17:43971206_CTAATT_C, within *MAPT-AS1* (microtubule associated protein tau – antisense RNA 1); rs4280294, within an unprocessed pseudogene *NSFP1* (N-Ethylmaleimide-Sensitive Factor Pseudogene 1); and rs79724577, 7.8kb upstream of *ARHGAP27* (rho GTPase activating protein 27). Functional analyses also implicated *MAPT-AS1* for expression in skeletal muscle (p_{TWAS}=2.2x10^{-09}, PP4=0.98), and *ARHGAP27* for expression in adipose, visceral omentum (p_{TWAS}=1.1x10^{-08}, PP4=0.93), brain (p_{TWAS}=3.1x10^{-07}, PP4=0.99), and heart, atrial appendage (p_{TWAS}=5.9x10^{-07}, PP4=0.75). *NSFP1* is a promoter/ enhancer for *KANSL1-AS1* (KAT8 regulatory NSL complex subunit 1 - antisense RNA 1) which showed strong evidence for correlation of expression with PA and colocalization with expression in adipose, artery, lung, and skeletal muscle tissues (p_{TWAS}<6.6 10^{-07} Bonferroni-corrected p-value for TWAS significance, PP4=0.99, for all tissues). The number of loci and the best positional candidates should be interpreted with caution as this is a gene dense region with many copy number variants, and 2 of the loci are situated within the large 17q21.31 inversion polymorphism (36, 37). Nonetheless, all 3 positional candidates were supported by the results of the functional analyses. The male-only variant rs67693719 on chromosome 6 is an intron variant of *IMPG1* (interphotoreceptor matrix proteoglycan 1).

In addition to the chromosome 17q21.31 functional candidates *MAPT-AS1, ARHGAP27,* and *KANSL1-AS1,* outside of this locus we identified TWAS-significant candidates *ACSF3* (acyl-coa synthetase family member) on chromosome 16q24.3 in adipose tissue (PP4=0.53).

Gene set enrichment

We also performed gene set enrichment analyses on the TWAS significant genes for sex-combined CRF-slope (20 genes: 20 with recognized Ensembl ID) and PA (23 genes: 22 with recognized Ensembl ID), as well as female PA (19 genes: 18 with recognized Ensembl ID). TWAS analyses of CRF-vo2max and the other sex-specific traits did not yield sufficient gene associations to perform enrichment analyses. Enrichment of TWAS-identified functional candidates in gene sets defined by genes identified in previous GWASs, reported in the GWAS Catalog, are **Figure S12** (CRF-slope combined) and **Figure S13** (PA combined and female).

CRF-slope functional genes were enriched in GWAS gene sets for blood pressure (systolic and diastolic) interactions with smoking and alcohol (FDR-adjusted p range=$4.0x10^{-02}$ – $2.5x10^{-07}$), heart rate response to exercise and recovery (FDR-adjusted p range=$3.0x10^{-05}$ – $2.1x10^{-05}$), the thrombosis and atherosclerosis risk factor *PAI-1* (plasminogen activator inhibitor-1: FDR-adjusted p=$5.3x10^{-06}$), coronary artery calcified atherosclerotic plaque in type 2 diabetes (FDR-adjusted p=$6.8x10^{-03}$), Alzheimer's disease (FDR-adjusted p=$2.7x10^{-02}$), as well as other physical (joint mobility: FDR-adjusted p=$8.5x10^{-03}$) and mental health traits (neuroticism: FDR-adjusted p=$5.5x10^{-10}$; and bipolar disorder: FDR-adjusted p=$8.5x10^{-03}$).

GWASs genes sets enriched PA functional candidates included disease (e.g., Alzheimer's disease, Parkinson's disease, and idiopathic pulmonary fibrosis), mental health traits (e.g., neuroticism, mood instability, and alcohol use disorder), as well as physical traits (e.g., male pattern baldness, reaction time). Enrichment for genes implicated in Alzheimer's (FDR-adjusted p=$9.1x10^{-05}$) and Parkinson's disease (FDR-adjusted p=$2.0x10^{-06}$) are noteworthy given there is some evidence of an underlying insulin resistance pathology. Also noteworthy were enrichment for lung function (FEV1 FDR-adjusted p=$4.7x10^{-02}$) given its use in the diagnosis and distinction between obstructive pulmonary diseases, and idiopathic pulmonary fibrosis (FDR-adjusted p=$1.2x10^{-05}$). The PA female enriched GWAS list was a subset of the PA combined sample list.

Genetic correlations within CRF-vo2max, CRF-slope, and PA

CRF-vo2max, CRF-slope and PA were all polygenic with modest SNP heritabilities of between 0.11 and 0.16 (**Table 2**). For the CRF phenotypes, males had slightly higher SNP heritability values than females.

Table 2. Heritability of CRF and PA

	CRF-vo2max	CRF-slope	PA
Combined	0.11 (0.01)	0.11 (0.03)	0.14 (0.01)
Male	0.12 (0.03)	0.13 (0.03)	0.14 (0.02)
Female	0.08 (0.03)	0.09 (0.05)	0.16 (0.01)

Note. Values shown are SNP heritabilities and standard errors on the observed scale. CRF-vo2max = maximum volume of oxygen uptake per kg of bodyweight per minute, estimated from workload and heart rate during the cardiorespiratory fitness test, as well as age and weight; CRF-slope = the rate of increase of heart rate during the exercise period of the cycle ramp test; PA = 7-day average physical activity

For the sex-combined between-phenotype genetic correlations, CRF-vo2max and CRF-slope were negatively correlated (r_g=-0.51, se=0.07, p=3.1x10^{-13}), suggesting genetic variants that contribute to greater fitness are also associated with a lower rate of increase of heart rate during exercise. PA had a moderate positive correlation with CRF-vo2max (r_g=0.37, se=0.06, p=4.2x10^{-10}), and a modest negative correlation with CRF-slope (r_g=-0.19, se=0.08, p=0.02). These two genetic correlations suggest that higher levels of activity have a shared genetic contribution with greater fitness, and with a lower rate of increase of heart rate during exercise. The within-sex between-phenotype genetic correlations were similar to those for the sex-combined results (supplementary **Figure S14**). Within-phenotype between-sex genetic correlations were all near 1.0, reflecting that the overall genomic signal is highly correlated despite a few different loci between sexes (supplementary **Figure S14**).

Genetic correlations with 702 traits and diseases

A comprehensive analysis of genetic correlations of CRF-vo2max, CRF-slope and PA with a wide array of traits was performed using LD-HUB (**Figure 5** shows the combined-sex result, **Figures S15–S17** show by-sex results). All genetic correlations described below were FDR-significant in the sex-combined sample. **Table S9** includes the sex-combined, male, and female FDR-significant genetic correlations, as well as heritabilities, associated standard errors, and GWAS study PubMed IDs for all FDR-significant traits and diseases.

Shared genetic risk: lipids, glycaemic, and cardiometabolic traits

Genetic variation associated with lower CRF-vo2max was correlated with features of the typical type-2 diabetes (T2D) profile: higher insulin resistance (HOMA-IR: r_g=-0.64, se=0.12) and higher fasting insulin (r_g=-0.62, se=0.10), impaired beta-cell function (HOMA-B: r_g=-0.39, se=0.11), lower high-density lipoprotein (HDL) cholesterol (r_g=0.37, se=0.08), hyperglycaemia (r_g=-0.29, se=0.08) and hypertriglyceridemia (r_g=-0.25, se=0.06). In the PA combined sample, as well as genetic correlations with fasting insulin (r_g=-0.25, se=0.07), HDL cholesterol (r_g=0.25, se=0.04), insulin resistance (r_g=-0.23, se=0.08), and triglycerides (r_g=-0.18, se=0.04), we observed a direct negative correlation with T2D (r_g=-0.25, se=0.05). Genetic variation associated with lower levels of physical activity was associated with increased risk of T2D.

Both CRF-vo2max and PA were negatively correlated with coronary artery disease (CRF-vo2max r_g=-0.26, se=0.06; PA r_g=-0.16, se=0.04). Like T2D, genetic variation associated with lower CRF-vo2max and lower PA was associated with increased risk for coronary artery disease. **Figure S18** highlights the FDR-significant glycaemic, cardiometabolic, and lipid traits in the combined sample, as well as in males and females separately.

For both CRF-vo2max and PA we observed positive FDR-significant genetic correlations with several related HDL metabolites. The largest HDL metabolite correlation with CRF-vo2max was with phospholipids in very large HDL (r_g=0.41, se=0.13). The largest correlation for PA was total cholesterol in medium HDL (r_g=0.43, se=0.15). Genetic variation associated with greater CRF-vo2max and PA were associated with higher levels of HDL.

CRF-slope was significantly negatively correlated with LDL metabolites: total lipids in chylomicrons and largest VLDL particles (r_g=-0.40, se=0.13), and total lipids in very large VLDL (r_g=-0.33, se=0.11). Genetic variants associated with greater CRF-slope was associated with lower lipids in VLDL molecules. **Figure S23** shows the genetic correlations with blood metabolites for the combined sample, and males and females separately.

Shared genetic risk: body and hormone measures

CRF-vo2max was positively genetically correlated with height (r_g=0.15, se=0.05) and extreme height (r_g=0.18, se=0.06). All other FDR-significant anthropometric correlations were negative (r_g=-0.35 – -0.57, se=0.05 – 0.09, for all traits): body fat, waist circumference, measures of obesity, BMI, waist-to-hip ratio and hip circumference. CRF-slope only had FDR-significant negative genetic correlations with childhood obesity (r_g=-0.24, se=0.08) and childhood height (r_g=-0.27, se=0.08). For the PA combined sample, shared many of the same genetic correlations as CRF-vo2max at a lower level of significance. For PA all FDR-significant body measures including height were negative (r_g=-0.11 – -0.36, se=0.03 – 0.05): body fat, waist circumference, measures of obesity, BMI, waist-to-hip ratio and hip circumference, and height. Genetic variation associated with greater CRF-vo2max and higher levels of PA was associated with lower body fat, BMI, obesity, and waist and hip circumferences. **Figures S19–S21** show FDR-significant genetic correlations with anthropometric and hormone measures for the combined sample and males and females separately.

Circulating levels of the satiety hormone leptin were negatively correlated with CRF-vo2max and PA (CRF r_g=-0.53, se=0.11; PA r_g=-0.35, se=0.07), and for PA was also significantly correlated with genetic risk for BMI-adjusted leptin (PA r_g=-0.26, se=0.06). The genetic profile associated with greater levels of fitness and activity is correlated with greater circulating levels of leptin, which inhibits hunger and reduces fat storage in adipocytes.

Shared genetic risk: lung function and heart rate

CRF-vo2max was moderately associated with lung function: forced vital capacity (FVC: r_g=0.23 – 0.28, se=0.06 – 0.08) and forced expiratory volume in 1 second (FEV1: r_g=0.21 – 0.27, se=0.06 – 0.08). For PA, we found a modest positive genetic correlation with FVC (r_g=0.12, se=0.04). Genetic variation associated with both fitness and activity is associated with improved lung function.

Only CRF-slope was genetically correlated with resting heart rate (r_g=-0.32, se=0.09). Genetic correlation associated with greater acceleration of heart rate during exercise was associated a lower resting heart rate, a correlation that

appears to be driven by the male subsample (r_g=-0.36, se=0.10). **Figure S22** shows genetic correlations with lung function and heart rate, for the combined sample and males and females separately.

Shared genetic risk: smoking behaviour, cancer, and longevity

We observed a negative genetic correlation with CRF-vo2max and ever vs never smoked (r_g=-0.22, se=0.07), and a positive genetic correlation between PA and former vs current smoking status (r_g=0.23, se=0.08). A genotype associated with greater levels of activity associated with smoking cessation, and genetic risk associated with ever smoking was associated with lower fitness. Only in CRF-vo2max did we find a substantial and significant correlation with cancer – squamous cell lung cancer (r_g=-0.47, se=0.15).

Finally, we found that genetic variation associated with greater CRF-vo2max and PA was also significantly associated with longevity, as measured by parents' ages at death (r_g=0.26 – 0.42, se=0.07 – 0.12). FDR-significant genetic correlations with smoking behaviour, cancer and longevity reported above are highlighted in **Figure S24**.

Discussion

Genetic variation explains a modest but significant proportion of the variation in vo2max, rate of increase of heart rate during exercise, and average weekly activity level, for both sexes. Genetic association signals were highly correlated between sexes, with only three SNPs that showed evidence for a sex-specific association (rs1268122 male CRF-vo2max, rs12542037 female CRF-slope, rs67693719 male PA). For PA, on which two previous GWASs have been performed in the UKB (14, 15), we did not replicate the chromosome 10 and 18 SNPs. Our analysis was not directly comparable given we performed a different set of QC steps on PA – notably removal of BMI outliers. The two derived fitness traits, CRF-vo2max (vo2max) and CRF-slope (rate of increase of heart rate during exercise), were negatively correlated, phenotypically and genetically. Greater levels of fitness correspond to a slower rate of increase of heart rate during exercise. CRF-vo2max was positively correlated with PA; greater fitness was associated with higher levels of physical activity.

Lower CAD and T2D among most fit and active

We found that higher levels of CRF-vo2max and PA were associated with better health outcomes in a dose-dependent way. The frequency of CAD and T2D diagnosis was substantially lower among individuals with higher levels of CRF-vo2max and PA, even after controlling for BMI and SES. In this large UK population-based sample, we find the same associations between PA and CRF-vo2max observed in epidemiological and clinical studies of coronary heart disease and cardiovascular events (39) and T2D (40). As has been previously observed (3), there was a noteworthy steeper drop-off in disease occurrence with increased PA and CRF-vo2max among the least fit and active third of the sample. The fitness and activity associations with disease observed in the combined sample were most stark among males. For

CRF-vo2max and CRF-slope, disease diagnosis frequency was generally lower as we only included individuals with no contraindications for the standard cycle ramp test protocol. Disease diagnosis association with CRF-slope was noisy, with no clear pattern of association.

Disease associated genes implicated in CRF and PA

Our functional genetic analyses identified genes associated with CRF and PA, with known associations in disease and clinical vital sign phenotypes. For CRF-vo2max, our one functional candidate *HINT3* (6q22.32) is highly conserved across species but has no known disease associations. The male-only association on chromosome 6, rs1268122, is intronic to *TRMT11* (6q22.32). *TRMT11* is significantly associated with survival, recurrence and aggressive forms of prostate cancer (41-43), but its relationship with CRF-vo2max is unclear.

For CRF-slope, functional candidates fell within one of two cytogenic regions. Functional candidates in cytogenic band 8p23.1 (*FAM167A*, *ERI1*, *MFHAS1*, *PPP1R3B*, *MSRA*, and *MTMR9*) were enriched among GWAS gene sets for a wide range of traits, most notably those related to the clinical vital sign blood pressure, and cardiovascular and diabetes phenotypes: blood pressure phenotypes (e.g. systolic and diastolic blood pressure interactions with smoking status and alcohol consumption), and the insulin resistance-related phenotypes Alzheimer's disease and coronary artery calcified atherosclerotic plaques in T2D. Functional candidate genes within 7q22.1 (*TRIP6*, *SRRT*, and *ACHE*) were notably enriched in traits related to the clinical vital sign heart rate and cardiovascular risk factors: heart rate phenotypes (response to and recovery from exercise), and the thrombosis and atherosclerosis risk factor *PAI-1*.

For PA, several genes in the 17q21.31 inversion polymorphism (*MAPT*, *ARHGAP27*, *KANSL1-AS1*, *PLEKHM1*, *CRHR1*, *LRRC37A2*, and *ARL17A*) were enriched in Alzheimer's and Parkinson's disease, noteworthy given their underlying insulin resistance pathology (although the insulin resistance link is controversial for Alzheimer's disease). Also noteworthy were enrichment in traits relating to respiratory function and disease: lung function (FEV1) given its use in the diagnosis and distinction between obstructive pulmonary diseases, and idiopathic pulmonary fibrosis.

Genetic correlations link CRF and PA with disease

Genetic correlations complement epidemiological and clinical observations. Because inherited genetic risk cannot be due to confounding, genetic correlations limit the number of potential confounders linked through genotype. The shared genetic architecture of both CRF-vo2max and PA clearly implicated the lifestyle-related chronic diseases obesity, T2D, and CAD, and their body composition and metabolic risk factors. CRF-vo2max and PA were negatively genetically correlated with obesity, body fat, body mass index, and waist-to-hip circumference, triglycerides, the satiety hormone leptin, fasting insulin, insulin resistance, and T2D (significant only for PA), and CAD. These negative genetic correlations corroborate the epidemiological associations, previous research findings, and clinical observations of CRF and PA and body composition (44, 45), lipid profile (46, 47), adipocytokines (48), fasting insulin and insulin resistance (49-53) and leptin (40), T2D (54-56), and CAD (57). Likewise, the positive genetic correlations are consistent with previous

observations of positive relationships between CRF and PA, and HDL cholesterol (47, 58) and longevity (59-61). Greater CRF-slope was negatively genetically correlated with resting heart rate and LDL metabolites.

Additionally, CRF-vo2max had positive genetic correlations with age at birth of first child and level of education, respectively a correlate and component of SES. This is consistent with population-based observations of a socioeconomic gradient in PA and CRF: people living in higher socioeconomic status areas tend to be more active and more fit, and from a public health perspective particularly important as "reduced PA and fitness levels may contribute to social inequalities in health" (62). CRF-slope had corresponding negative correlations with higher levels of education, birth of a first child later in life and completing college.

We note several limitations. The gold standard for CRF measurement involves exercise to volitional exhaustion with measurement of gas exchange (uptake of oxygen, elimination of carbon dioxide). A submaximal CRF test with extrapolation of VO2max scores is however a much more practical solution, especially for the collection of large samples in the age ranges studied. The objective PA monitoring only captured a 7-day window, effectively a snapshot of participant behaviour, and we do not know if this reflects their habitual behaviour. We also used raw acceleration and did not attempt to tease apart PA intensity, recognized as important for health outcomes. All genetic associations, especially the sex-specific SNPs identified, will require replication in an independent sample. In our genetic correlation analyses, some of the largest correlations were observed with blood metabolites but these were based on relatively small GWAS reference samples (metabolites N=24,925 compared to body fat N=100,716) and many metabolite correlations failed to pass the multiple testing threshold. As well as this sample size (or power of each discovery GWAS) limitation, genetic correlations cannot resolve reverse causation. Another limitation is correlated lifestyle risk factors not considered, in particular eating behaviours and nutrition. Eating habits, diet, and exercise behaviours tend to go hand in hand, in large part influenced by the environment, e.g., sedentary time spent watching television and eating high-fat foods (63, 64). A holistic approach to health – addressing eating habits and including an effective dietary intervention (65), alongside prescription PA and monitoring of CRF – may be the most effective practical approach, especially in already overweight individuals given the possibility that there exists a bi-directional relationship between adiposity and PA (66). Despite the complex interplay of eating habits, nutrition, environment, and PA, CRF as a regularly measured vital sign is an objective and easily measured sentinel for health.

Conclusions

In summary, we found strong evidence that genetic variants associated with CRF and PA also influenced genetic expression in a small set of genes in heart, artery, lung, muscle, and adipose tissue. These functionally relevant genes were enriched among genes known to be associated with CAD, T2D and Alzheimer's disease – three of the top 10 causes of death in high-income countries – as well as Parkinson's, pulmonary fibrosis, and blood pressure, heart rate, and respiratory phenotypes. Finally, genetic correlation related lower fitness and activity with several disease risk factors including greater waist-to-hip ratio, BMI, and obesity; with a typical T2D profile including higher insulin

resistance, higher fasting glucose, impaired beta-cell function, hyperglycaemia, hypertriglyceridemia; increased risk for CAD and T2D; and shorter lifespan. Genetics supports three decades of evidence for the inclusion of CRF as a clinical vital sign (3). CRF is a window onto general health and wellbeing, and physical activity is the primary means of improving CRF. In fact, to meet the WHO policy of reduction in sedentary lifestyles that carry a heavy cost to personal and public health, "policies to increase population levels of physical activity need to be prioritised and scaled up urgently" (8). Given the global health burden of non-communicable disease related to lifestyle choices, as well as dietary advice, regular measurement of CRF as a marker of health and routine prescription of PA is imperative.

Figure captions

Figure 1. Raw heart rate and cadence. Panel **A** shows the heart rate and panel **B** the cadence for 1000 random samples drawn from the initial assessment and first repeat assessment combined. Trend = repeated measurement points during the submaximal cycle ramp test (a proxy for time); Heart Rate (BPM) = 4-lead electrocardiograph (ECG) heart rate data; Cadence (RPM) = stationary bicycle pedal speed – instruction was to cycle at 60 revolutions per minute

Figure 2. Disease frequency by CRF and PA level. Frequency in the UKB for the top 10 global causes of death in high-income countries in 2016, as reported by the World Health Organization (WHO). The CRF and PA phenotypes above are controlled for age and socioeconomic status (SES, the Townsend deprivation index) – they are the residuals from a regression on age and SES. For all phenotypes, we removed BMI outliers as part of the phenotype QC. For the CRF phenotypes vo2max and slope, diagnosis frequency is generally lower in this group which was the "healthiest" group selected to perform the cycle ramp test protocol 1. The apparent increase in ischaemic heart disease with CRF-vo2max, apparent decrease in ischaemic heart disease with CRF-slope, and apparent increase in breast cancer with CRF-slope seen in the combined sample is a consequence of the higher CRF-vo2max and lower CRF-slope in males than females (**Figure S2**). Disease trends are only meaningful separated by sex.

Figure 3. Genome-wide association signal by sex for CRF-vo2max, CRF-slope, and PA. The red line shows genome-wide significance, $p=5x10^{-08}$.

Figure 4. TWAS and colocalization identified genes. Genes listed on the y-axes are significant at the conservative Bonferroni corrected TWAS p-value. On the x-axis is tissue type; category of tissue is represented by colour, colocalization posterior probability 4 (COLOC PP4 – the probability of a shared causal SNP driving the association signal and expression in a reference tissue) represented by line angle (vertical line is a probability of 1.0 that the GWAS-identified SNP is an eQTL for the gene). The complementary TWAS and colocalization approaches provide a priority list of genes for further exploration. Genes in bold were significant in the gene-based test of association.

Figure 5. Genetic correlations for combined males and females. red = negative correlations; blue = positive correlations; size = relative size of the genetic correlation

List of abbreviations

CRF = cardiorespiratory fitness, PA = physical activity, AHA = American Heart Association, UKB = UK Biobank, CRF-vo2max = an estimate of the participants' maximum volume of oxygen uptake, per kilogram of body weight, per minute, CRF-slope = an estimate of the rate of increase of heart rate during exercise, GWAS = genome-wide association study, CAD = coronary artery disease, T2D = type 2 diabetes, h^2 = heritability, h^2_{SNP} = SNP heritability, ECG = electrocardiograph, BMI = body mass index, HR = heart rate, WL = workload, WHO = world health organization, ICD-10 = International Classification of Diseases revision 10, SES = socioeconomic status, TWAS = transcriptome-wide association, FDR = false-discovery rate

Declarations

Ethics approval and consent to participate

Ethics approval for the UK Biobank study was obtained from the North West Centre for Research Ethics Committee (11/NW/0382); participants provided electronic signed consent at recruitment.

Competing interests

The authors declare that they have no competing interests.

Funding

This research was funded by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) South London and Maudsley, and Guy's and St Thomas', NHS Foundation Trusts, and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. CML receives funding from a UK Medical Research Council (MRC) grant (MR/N015746/1).

Authors' contributions

KBH, MH, CML conceived and designed the study. KBH analysed the data. KBH, EP, MT, KPG, MH, JRIC, CML interpreted the results and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This research has been conducted as part of UKB project 13427 (PI: CML). We would like to acknowledge the UKB participants for their contributions.

References

1. DeFina LF, Haskell WL, Willis BL, Barlow CE, Finley CE, Levine BD, et al. Physical activity versus cardiorespiratory fitness: two (partly) distinct components of cardiovascular health? Prog Cardiovasc Dis. 2015;57(4):324-9.

2. Lavie CJ, Johannsen N, Swift D, Senechal M, Earnest C, Church T, et al. Exercise is Medicine - The Importance of Physical Activity, Exercise Training, Cardiorespiratory Fitness and Obesity in the Prevention and Treatment of Type 2 Diabetes. Eur Endocrinol. 2014;10(1):18-22.

3. Ross R, Blair SN, Arena R, Church TS, Despres JP, Franklin BA, et al. Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association. Circulation. 2016;134(24):e653-e99.

4. Tipton CM. The history of "Exercise Is Medicine" in ancient civilizations. Adv Physiol Educ. 2014;38(2):109-17.

5. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238-45.

6. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, et al. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012;380(9838):219-29.

7. Ding D, Lawson KD, Kolbe-Alexander TL, Finkelstein EA, Katzmarzyk PT, van Mechelen W, et al. The economic burden of physical inactivity: a global analysis of major non-communicable diseases. Lancet. 2016;388(10051):1311-24.

8. Guthold R, Stevens GA, Riley LM, Bull FC. Worldwide trends in insufficient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants. Lancet Glob Health. 2018;6(10):e1077-e86.

9. Teran-Garcia M, Rankinen T, Bouchard C. Genes, exercise, growth, and the sedentary, obese child. J Appl Physiol (1985). 2008;105(3):988-1001.

10. den Hoed M, Brage S, Zhao JH, Westgate K, Nessa A, Ekelund U, et al. Heritability of objectively assessed daily physical activity and sedentary behavior. Am J Clin Nutr. 2013;98(5):1317-25.

11. Timmons JA, Knudsen S, Rankinen T, Koch LG, Sarzynski M, Jensen T, et al. Using molecular classification to predict gains in maximal aerobic capacity following endurance exercise training in humans. J Appl Physiol (1985). 2010;108(6):1487-96.

12. Bouchard C, Sarzynski MA, Rice TK, Kraus WE, Church TS, Sung YJ, et al. Genomic predictors of the maximal O(2) uptake response to standardized exercise training programs. J Appl Physiol (1985). 2011;110(5):1160-70.

13. Williams CJ, Williams MG, Eynon N, Ashton KJ, Little JP, Wisloff U, et al. Genes to predict VO2max trainability: a systematic review. BMC Genomics. 2017;18(Suppl 8):831.

14. Klimentidis YC, Raichlen DA, Bea J, Garcia DO, Wineinger NE, Mandarino LJ, et al. Genome-wide association study of habitual physical activity in over 377,000 UK Biobank participants identifies multiple variants including CADM2 and APOE. Int J Obes (Lond). 2018.

15. Doherty A, Smith-Bryne K, Ferreira T, Holmes MV, Holmes C, Pulit S, et al. GWAS identifies 14 loci for device-measured physical activity and sleep duration. Nature Communications. 2018;9(5257).

16. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203-9.

17. Wilson MG, Ellison GM, Cable NT. Basic science behind the cardiovascular benefits of exercise. Brit J Sport Med. 2016;50(2):93-+.

18. Karastergiou K, Smith SR, Greenberg AS, Fried SK. Sex differences in human adipose tissues - the biology of pear shape. Biol Sex Differ. 2012;3.

19. Valencak TG, Osterrieder A, Schulz TJ. Sex matters: The effects of biological sex on adipose tissue biology and energy metabolism. Redox Biol. 2017;12:806-13.

20. van Uffelen JGZ, Khan A, Burton NW. Gender differences in physical activity motivators and context preferences: a population-based study in people in their sixties. BMC Public Health. 2017;17(1):624.

21. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.

22. Celis-Morales CA, Lyall DM, Anderson J, Iliodromiti S, Fan Y, Ntuk UE, et al. The association between physical activity and risk of mortality is modulated by grip strength and cardiorespiratory fitness: evidence from 498 135 UK-Biobank participants. Eur Heart J. 2017;38(2):116-22.

731 23. Tanaka H, Monahan KD, Seals DR. Age-predicted maximal heart rate revisited. J Am Coll Cardiol.
732 2001;37(1):153-6.

733 24. Swain DP. Energy cost calculations for exercise prescription: an update. Sports Med. 2000;30(1):17-22.

734 25. Doherty A, Jackson D, Hammerla N, Plotz T, Olivier P, Granat MH, et al. Large Scale Population Assessment of
735 Physical Activity Using Wrist Worn Accelerometers: The UK Biobank Study. PLoS One. 2017;12(2):e0169649.

736 26. Team RC. R: A Language and Environment for Statistical Computing. 2018.

737 27. Rossum Gv. Python tutorial. Centrum voor Wiskunde en Informatica (CWI). 1995(CS-R9526).

738 28. Koster J, Rahmann S. Snakemake--a scalable bioinformatics workflow engine. Bioinformatics.
739 2012;28(19):2520-2.

740 29. Hanscombe KB, Coleman RI, Traylor M, Lewis CM. ukbtools: An R package to manage and query UK Biobank
741 data. PLoS One. 2019.

742 30. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge
743 of larger and richer datasets. Gigascience. 2015;4:7.

744 31. Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the Psychiatric
745 Genomics C, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies.
746 Nature Genetics. 2015;47:291.

747 32. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, et al. Integrative approaches for large-scale
748 transcriptome-wide association studies. Nat Genet. 2016;48(3):245-52.

749 33. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic
750 associations with FUMA. Nat Commun. 2017;8(1):1826.

751 34. Zheng J, Erzurumluoglu AM, Elsworth BL, Kemp JP, Howe L, Haycock PC, et al. LD Hub: a centralized database
752 and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP
753 heritability and genetic correlation analysis. Bioinformatics. 2017;33(2):272-9.

754 35. Aschard H, Vilhjalmsson BJ, Joshi AD, Price AL, Kraft P. Adjusting for heritable covariates can bias effect
755 estimates in genome-wide association studies. Am J Hum Genet. 2015;96(2):329-39.

36. Stefansson H, Helgason A, Thorleifsson G, Steinthorsdottir V, Masson G, Barnard J, et al. A common inversion under selection in Europeans. Nat Genet. 2005;37(2):129-37.

37. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun. 2013;4:1627.

38. Ramirez J, Duijvenboden SV, Ntalla I, Mifsud B, Warren HR, Tzanis E, et al. Thirty loci identified for heart rate response to exercise and recovery implicate autonomic nervous system. Nat Commun. 2018;9(1):1947.

39. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA. 2009;301(19):2024-35.

40. Lin X, Zhang X, Guo J, Roberts CK, McKenzie S, Wu WC, et al. Effects of Exercise Training on Cardiorespiratory Fitness and Biomarkers of Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2015;4(7).

41. Zhang BY, Riska SM, Mahoney DW, Costello BA, Kohli R, Quevedo JF, et al. Germline genetic variation in JAK2 as a prognostic marker in castration-resistant prostate cancer. BJU Int. 2017;119(3):489-95.

42. Yu YP, Liu P, Nelson J, Hamilton RL, Bhargava R, Michalopoulos G, et al. Identification of recurrent fusion genes across multiple cancer types. Sci Rep. 2019;9(1):1074.

43. Yu YP, Ding Y, Chen Z, Liu S, Michalopoulos A, Chen R, et al. Novel fusion transcripts associate with progressive prostate cancer. Am J Pathol. 2014;184(10):2840-9.

44. L. dL, R. R. Physical Activity, Cardiorespiratory Fitness, and Obesity. In: P. K, P. N, editors. Cardiorespiratory Fitness in Cardiometabolic Diseases: Springer; 2019.

45. Prioreschi A, Brage S, Westgate K, Norris SA, Micklesfield LK. Cardiorespiratory fitness levels and associations with physical activity and body composition in young South African adults from Soweto. BMC Public Health. 2017;17(1):301.

46. Sui X, Sarzynski MA, Lee DC, Kokkinos PF. Impact of Changes in Cardiorespiratory Fitness on Hypertension, Dyslipidemia and Survival: An Overview of the Epidemiological Evidence. Prog Cardiovasc Dis. 2017;60(1):56-66.

47. Breneman CB, Polinski K, Sarzynski MA, Lavie CJ, Kokkinos PF, Ahmed A, et al. The Impact of Cardiorespiratory Fitness Levels on the Risk of Developing Atherogenic Dyslipidemia. Am J Med. 2016;129(10):1060-6.

783 48. Martinez-Gomez D, Eisenmann JC, Gomez-Martinez S, Veses A, Romeo J, Veiga OL, et al. Associations of
784 physical activity and fitness with adipocytokines in adolescents: the AFINOS Study. Nutr Metab Cardiovasc Dis.
785 2012;22(3):252-9.

786 49. Bird SR, Hawley JA. Update on the effects of physical activity on insulin sensitivity in humans. BMJ Open Sport
787 Exerc Med. 2016;2(1):e000143.

788 50. Henderson M, Benedetti A, Barnett TA, Mathieu ME, Deladoey J, Gray-Donald K. Influence of Adiposity,
789 Physical Activity, Fitness, and Screen Time on Insulin Dynamics Over 2 Years in Children. JAMA Pediatr.
790 2016;170(3):227-35.

791 51. Gill JM. Physical activity, cardiorespiratory fitness and insulin resistance: a short update. Curr Opin Lipidol.
792 2007;18(1):47-52.

793 52. Hamer M, O'Donovan G. Cardiorespiratory fitness and metabolic risk factors in obesity. Curr Opin Lipidol.
794 2010;21(1):1-7.

795 53. Nystrom CD, Henriksson P, Martinez-Vizcaino V, Medrano M, Cadenas-Sanchez C, Arias-Palencia NM, et al.
796 Does Cardiorespiratory Fitness Attenuate the Adverse Effects of Severe/Morbid Obesity on Cardiometabolic Risk and
797 Insulin Resistance in Children? A Pooled Analysis. Diabetes Care. 2017;40(11):1580-7.

798 54. Aune D, Norat T, Leitzmann M, Tonstad S, Vatten LJ. Physical activity and the risk of type 2 diabetes: a
799 systematic review and dose-response meta-analysis. Eur J Epidemiol. 2015;30(7):529-42.

800 55. Rohling M, Strom A, Bonhof G, Puttgen S, Bodis K, Mussig K, et al. Differential Patterns of Impaired
801 Cardiorespiratory Fitness and Cardiac Autonomic Dysfunction in Recently Diagnosed Type 1 and Type 2 Diabetes.
802 Diabetes Care. 2017;40(2):246-52.

803 56. Juraschek SP, Blaha MJ, Blumenthal RS, Brawner C, Qureshi W, Keteyian SJ, et al. Cardiorespiratory fitness and
804 incident diabetes: the FIT (Henry Ford Exercise Testing) project. Diabetes Care. 2015;38(6):1075-81.

805 57. Myers J, McAuley P, Lavie CJ, Despres JP, Arena R, Kokkinos P. Physical activity and cardiorespiratory fitness as
806 major markers of cardiovascular risk: their independent and interwoven importance to health status. Prog Cardiovasc
807 Dis. 2015;57(4):306-14.

808 58. O'Donovan G, Hillsdon M, Ukoumunne OC, Stamatakis E, Hamer M. Objectively measured physical activity,
809 cardiorespiratory fitness and cardiometabolic risk factors in the Health Survey for England. Prev Med. 2013;57(3):201-5.

59. Moore SC, Patel AV, Matthews CE, Berrington de Gonzalez A, Park Y, Katki HA, et al. Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. PLoS Med. 2012;9(11):e1001335.

60. Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Netw Open. 2018;1(6):e183605.

61. Chudasama YV, Khunti KK, Zaccardi F, Rowlands AV, Yates T, Gillies CL, et al. Physical activity, multimorbidity, and life expectancy: a UK Biobank longitudinal study. BMC Med. 2019;17(1):108.

62. Lindgren M, Borjesson M, Ekblom O, Bergstrom G, Lappas G, Rosengren A. Physical activity pattern, cardiorespiratory fitness, and socioeconomic status in the SCAPIS pilot trial - A cross-sectional study. Prev Med Rep. 2016;4:44-9.

63. Hill JO, Peters JC. Environmental contributions to the obesity epidemic. Science. 1998;280(5368):1371-4.

64. French SA, Story M, Jeffery RW. Environmental influences on eating and physical activity. Annu Rev Public Health. 2001;22:309-35.

65. Wright N, Wilson L, Smith M, Duncan B, McHugh P. The BROAD study: A randomised controlled trial using a whole food plant-based diet in the community for obesity, ischaemic heart disease or diabetes. Nutr Diabetes. 2017;7(3):e256.

66. Richmond RC, Davey Smith G, Ness AR, den Hoed M, McMahon G, Timpson NJ. Assessing causality in the association between child adiposity and physical activity levels: a Mendelian randomization analysis. PLoS Med. 2014;11(3):e1001618.


A
B
Heart rate (BPM)
175
150
125
100
75
50
Cadence (RPM)
100
75
50
25
0
0
20
40
60
80
100
Trend
Pretest
Exercise
Rest


UKB diagnosis frequency
15%
10%
5%
0%
-20
-10
0
10
20
CRF-vo2max combined
CRF-vo2max male
CRF-vo2max female
-0.25
0.00
0.25
CRF-slope combined
CRF-slope male
CRF-slope female
PA combined
PA male
PA female
alzheimer's disease and other dementias
breast cancer
chronic obstructive pulmonary disease
colon and rectum cancers
diabetes mellitus
ischaemic heart disease
kidney diseases
lower respiratory tract infections
stroke
trachea, bronchus and lung cancers


CRF-vo2max
CRF-slope
PA
combined
female
male
$-\log_{10}(p)$
Chromosome


CRF-vo2max
CRF-slope
PA
TRIP6: 7q22.1
SRRT: 7q22.1
SESTD1: 2q31.2
RPS26P8: 17q21.31
RP11-798G7.8: 17q21.31
RP11-798G7.5: 17q21.31
RP11-707O23.5: 17q21.31
RP11-62H7.2: 8p23.1
RP11-259G18.3: 17q21.31
RP11-259G18.2: 17q21.31
RP11-259G18.1: 17q21.31
RP11-148O21.2: 8p23.1
RP11-10A14.5: 8p23.1
PPP1R3B: 8p23.1
PLEKHM1: 17q21.31
MTMR9: 8p23.1
MSRA: 8p23.1
MFHAS1: 8p23.1
MAPT: 17q21.31
MAPT-AS1: 17q21.31
LRRC37A4P: 17q21.31
LRRC37A2: 17q21.31
KIAA1267: 17q21.31
KANSL1: 17q21.31
KANSL1-AS1: 17q21.31
HINT3: 6q22.31
FAM86B3P: 8p23.1
FAM85B: 8p23.1
FAM66D: 8p23.1
FAM66A: 8p23.1
FAM215B: 17q21.31
FAM167A: 8p23.1
ERI1: 8p23.1
DND1P1: 17q21.31
DND1: 17q21.31
CRHR1: 17q21.31
CRHR1-IT1: 17q21.31
CPEB1: 15q25.2
COG4: 16q22.1
ARL17A: 17q21.31
ARHGAP27: 17q21.31
ALG1L13P: 8p23.1
AF131215.9: 8p23.1
AF131215.5: 8p23.1
AF131215.2: 8p23.1
ACSF3: 16q24.3
ACHE: 7q22.1
adipose_subcutaneous
adipose_visceral_omentum
artery_aorta
artery_coronary
artery_tibial
cmc.brain.rnaseq
heart_atrial_appendage
heart_left_ventricle
lung
metsim.adipose.rnaseq
muscle_skeletal
ntr.blood.rnaarr
yfs.blood.rnaarr
adipose
blood
heart
muscle
artery
brain
lung
PP4
0.00
0.25
0.50
0.75
1.00


CRF−vo2max
CRF−slope
PA
−log10(p)
Bonferroni threshold
False discovery rate threshold
education
anthropometric
reproductive
glycemic
lung_function
lipids
hormone
cardiometabolic
aging
psychiatric
cancer
metabolites
smoking_behaviour
other
sleeping
haemotological
cognitive
autoimmune
brain_volume
metal
bone
personality
kidney
neurological
uric_acid
rg >= 0
FALSE
TRUE
abs(rg)
0.2
0.4
0.6